Overview

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

Status:
Completed

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Peregrine Pharmaceuticals

Treatments:

Antibodies, Monoclonal
Bavituximab
Docetaxel